|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.150 AUD | -3.38% |
|
-4.69% | -26.57% |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| 04-28 | Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 341M | |||||
| 71.04B | |||||
| 52.43B | |||||
| 43.84B | |||||
| 33.99B | - | ||||
| 28.49B |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition